Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Monica Graziutti"'
Autor:
Meera Mohan, Sravani Gundarlapalli, Aniko Szabo, Naveen Yarlagadda, Sunilkumar Kakadia, Manojna Konda, Anusha Jillella, Amisha Fnu, Yetunde Ogunsesan, Lakshmi Yarlagadda, Nishant Thalambedu, Hussain Munawar, Monica Graziutti, Samer Al Hadidi, Daisy Alapat, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Carolina Schinke
Publikováno v:
American Journal of Hematology. 97
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f40aa730ab5461e8a0649a3f2ff8aab
https://doi.org/10.1002/ajh.26530
https://doi.org/10.1002/ajh.26530
Autor:
Kristin Larsen, Horace Spencer, Meera Mohan, Clyde Bailey, Kerri Hill, Mathew Kottarathara, Richa Parikh, Shadiqul Hoque, Amani Erra, Angel Mitma, Pankaj Mathur, Lakshmi Yarlagadda, Sravani Gundarlapalli, Yetunde Ogunsesan, Munawwar Hussain, Nishanth Thalambedu, Jaskirat Sethi, Samer Al Hadidi, Sharmilan Thanendrarajan, Monica Graziutti, Maurizio Zangari, Bart Barlogie, Frits van Rhee, Guido Tricot, Carolina Schinke
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 6; Pages: 1640
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for multiple myeloma (MM) patients. Although outpatient ASCT has been shown to be safe and feasible, the procedure is overall rare with most p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6fb13bed5db05b3a6da0aa37f8e9972
https://pubmed.ncbi.nlm.nih.gov/35329966
https://pubmed.ncbi.nlm.nih.gov/35329966
Autor:
Sravani Gundarlapalli, Clyde Bailey, Shadiqul Hoque, Reid D. Landes, Angel A Mitma, Guido Tricot, Carolina Schinke, Kerri Hill, Yetunde Ogunsesan, Mathew Kottarathara, Monica Graziutti, Maurizio Zangari, Lakshmi Yarlagadda, Richa Parikh, Frits van Rhee, Sharmilan Thanendrarajan, Meera Mohan
Publikováno v:
Cancers
Volume 13
Issue 16
Cancers, Vol 13, Iss 4019, p 4019 (2021)
Volume 13
Issue 16
Cancers, Vol 13, Iss 4019, p 4019 (2021)
Simple Summary Multiple Myeloma (MM) is the most common cancer of the bone marrow and remains incurable despite advances in novel therapy. The disease course is typically characterized by an initial response pattern to treatment followed by eventual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4f6d44065654f832c9cca1bdd477ab0
https://doi.org/10.3390/cancers13164019
https://doi.org/10.3390/cancers13164019
Autor:
Elias Kiwan, John D. Shaughnessy, Klaus Hollmig, Yazan Alsayed, Mauricio Pineda-Roman, John Crowley, Jeffrey Haessler, Bart Barlogie, Elias Anaissie, Frits van Rhee, Monica Graziutti, Sarah Waheed
Publikováno v:
Blood. 112:162-162
We have previously reported on the remarkable activity of the TT3 program that incorporated both bortezomib (V) and thalidomide (T) into the up-front management of 303 patients. TT3 consisted of 2 cycles each of induction prior to and of dose-reduced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c52ea4c227b1a5003b9f1feeb7ed451b
https://doi.org/10.1182/blood.v112.11.162.162
https://doi.org/10.1182/blood.v112.11.162.162